Patient Attributes for Optimal Treatment Outcome in Irritable Bowel Syndrome. (IBS)
Recruitment status was Not yet recruiting
The purpose of this study is to determine if any specific patient characteristics lead to improved outcome of IBS treatment, when conventional treatment as well as Cognitive Behavioral Therapy is used in combination.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
|Official Title:||Examining Patient Attributes To Determine Optimal Treatment Outcome in Irritable Bowel Syndrome.|
- IBS Quality of Life Inventory(IBS QOLF) [ Time Frame: 6 months ] [ Designated as safety issue: No ]Significant improvement in IBS QOLF score in the treatment group
- Behavioral Symptom Inventory [ Time Frame: 6 months ] [ Designated as safety issue: No ]improvement in emotional function
|Study Start Date:||April 2011|
|Estimated Study Completion Date:||December 2011|
|Estimated Primary Completion Date:||December 2011 (Final data collection date for primary outcome measure)|
No Intervention: Control group
Patients in this group will receive conventional treatment for IBS, including anti-diarrhea agents, laxatives, bulking agents and anti-spasmodic.
Patients in this group will receive conventional treatment for IBS, but in addition will receive 6 weeks of CBT
Behavioral: Cognitive Behavior Therapy(CBT)
Cognitive Behavior Therapy(CBT) for 6 weeks.
Other Name: Cognitive Behavior Therapy(CBT)
Although research has demonstrated the efficacy of various psychological and pharmacological treatments for irritable bowel syndrome (IBS)1, health professionals have limited information about how to determine which specific treatment regimens lead to optimal outcomes for specific IBS populations 2,3. A prevalent syndrome, with high healthcare costs, IBS is a debilitating chronic functional bowel disorder with increasingly interconnected psychosocial and gastrointestinal afflictions4. In general, IBS sufferers have not been found to respond consistently to a single medication or class of medications5. In the wake of the failures of medical therapies, many psychological interventions, adjunct to standard IBS treatments, have been examined1,6 such as Blanchard and Scharff's 2002 review of 12 random controlled trials that found strong evidence for the utility of hypnotherapy, cognitive behavioral therapy (CBT), and brief psychodynamic psychotherapy in helping to alleviate IBS symptoms7. Similarly, in a more recent study involving a meta-analysis of seventeen studies, with randomized trials comparing classes of psychological interventions, found that these psychological treatments also play a role in improving quality of life of IBS suffers1. Among these psychological interventions, cognitive behavioral therapy (CBT), a prescriptive therapy that specifically targets faulty thinking patterns, has been found to be quite effective in many empirical investigations. Recent evaluations of CBT interventions have found the therapy to have a direct effect on global improvements of IBS symptoms and quality of life8. Despite its demonstrated effectiveness, however, CBT does not work for all patients3,6,8. The successes of medical therapy alone compared to a treatment regimen combining psychological and pharmaceutical interventions have been greeted with mixed results— leading to the unnecessary waste of health resources in the course of treatment3,6. To decrease medical costs, as well to foster optimal treatment for IBS patients, there is a need for a better method of identifying which patients will most benefit from specific treatment options s (i.e. conventional medical treatment versus standard treatment and CBT)2,3.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01297556
|Contact: Iftiker Ahmad, M.D.||517.332.1200 ext firstname.lastname@example.org|
|Contact: Priscilla Wade, Ph.Demail@example.com|
|United States, Michigan|
|Michigan Gastroenterology Institute||Not yet recruiting|
|East Lansing, Michigan, United States, 48823|
|Contact: Iftiker Ahmad, M.D. 517-332-1200 ext 221|
|Principal Investigator: Iftiker Ahmad, M.D.|
|Principal Investigator:||Iftiker Ahmad, M.D.||Michigan Gastroenterology Institute|